Du är här

2014-04-24

Galapagos NV: Baker Brothers notify of 4.99% shareholding in Galapagos

Mechelen, Belgium; 24 April 2014 - Galapagos NV (Euronext: GLPG) received
notice that Baker Brothers Life Sciences L.P.,
667 L.P. and 14159 L.P.
currently collectively hold 4.99% of outstanding Galapagos shares.

Pursuant to Belgian transparency legislation[1], Galapagos received notice on
18 April 2014 from Baker Brothers Life Sciences L.P., stating that Baker
Brothers Life Sciences L.P., 667 L.P. and 14159 L.P. collectively held
1,503,314 shares. This represents 4.99% of the 30,098,837 Galapagos shares
currently outstanding and marks a decrease from the 1,722,066 shares
previously held by Baker Brothers Life Sciences L.P., 667 L.P. and 14159
L.P., as notified on 10 July 2012.

About Galapagos
Galapagos(Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline comprising five Phase 2 studies (two led by GSK), one
Phase 1 study, six pre-clinical, and 20 discovery small-molecule and antibody
programs in cystic fibrosis, inflammation, antibiotics, metabolic disease,
and other indications. In the field of inflammation, AbbVie and Galapagos
signed a worldwide license agreement whereby AbbVie will be responsible for
further development and commercialization ofGLPG0634after Phase 2B. GLPG0634
is an orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases, currently
in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Selective JAK1
inhibitor GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012) met the primary endpoint in a Phase 2 study in psoriasis. An
exploratory Phase 1/2 study in ulcerative colitis is currently on hold.
GLPG0974is the first inhibitor of FFA2 to be evaluated clinically for the
treatment of IBD; this program is currently in a Proof-of-Concept Phase 2
study. GLPG1205is a first-in-class molecule that targets inflammatory
disorders and has completed Phase 1. AbbVie and Galapagos signed an
agreement in CF whereby they work collaboratively to develop and
commercialize oral drugs that address two mutations in the CFTR gene, the
G551D and F508del mutation. Potentiator GLPG1837 is at the pre-clinical
candidate stage. Galapagos has 400 employees, operating from its Mechelen,
Belgium headquarters and facilities in The Netherlands, France, and Croatia.
Further information at:www.glpg.com

For media and investor inquiries:
Elizabeth Goodwin, Head of Corporate Communications&Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com

This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
regulation.
---------------------------------------[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in
issuers whose shares are admitted to trading on a regulated market.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire

HUG#1779700

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.